Disease
Chronic Kidney Disease
Progressive loss of kidney function (reduced eGFR and/or albuminuria) over 3+ months, spanning stages 1-5 up to but not including dialysis-dependent end-stage renal disease.
Coverage in progress. AssetMemo has not yet run its full census for Secondary Hyperparathyroidism, so the assets listed for it are not complete.
Combined attributable cost
$646.5B+
Drug spend
$50.3B+
8% of total cost is drugs
Sum of 2 indications below.